trending Market Intelligence /marketintelligence/en/news-insights/trending/80rHUrcbwMz27OpUaHT6ag2 content esgSubNav
In This List

Amgen's cancer therapy meets primary endpoint in phase 2 study

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Amgen's cancer therapy meets primary endpoint in phase 2 study

Amgen Inc. said the phase 2 trial of Imlygic, in combination with Bristol-Myers Squibb Co.'s Yervoy, met its main goal in an aggressive form of skin cancer.

The study showed that a higher number of unresectable advanced melanoma patients 38.8% experienced a reduction in their tumor compared to 18% for those on Yervoy alone.

Patients on the combination arm were also able to keep their disease at bay for an average of 8.2 months compared to 6.4 months in the Yervoy arm. Amgen said the effect was not statistically significant, but further analysis is pending.